Who we are
Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health.

By leveraging its proprietary expertise in nitric oxide-donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma.

Two of the Company’s products are currently at the pre-approval stage with the U.S. Food and Drug Administration (FDA), including latanoprostene bunod, an intra-ocular pressure (IOP)-lowering treatment for glaucoma that has been licensed worldwide to Bausch + Lomb, and AC-170, a novel eye drop formulation of cetirizine for allergic conjunctivitis.

In addition, the Company has a growing pipeline targeting ophthalmic conditions including glaucoma / IOP reduction and blepharitis, and as well promising next-generation stand alone nitric-oxide donors.

The Company’s strategy is to maximise the potential of its technology and products through in-house development and industry-leading collaborations.

Nicox, which is headquartered in Sophia Antipolis, France, was formed in 1996 and has been listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) since 1999. Nicox has research facilities in Bresso, Italy, and a U.S. office in Fort Worth, Texas.

Our approach
The global ophthalmic market was valued at over $22 billion in 2015 and is estimated to reach over $37 billion in 2026.

Addressing a gap in the ophthalmic market

Certain areas, such as retinal conditions and dry eye, are expected to experience considerable growth due to a significant need for better treatments and diagnostic options. The ophthalmic market is currently dominated by large global pharmaceutical companies and much smaller national players. We see the opportunity for a targeted R&D organisation in ophthalmology.

Our experienced team brings together a heritage of scientific, financial, business and corporate development expertise, strengthened by our own in-house research capabilities.

Our route for growth is based on the confirmed potential of our proprietary NO-donating research platform, our other proprietary development assets and our partnered programs.  We intend to develop our portfolio through outstanding international collaborations and internal focus on our proprietary developments.



Ophthalmology Drugs Market Forecast 2016-2026, Visiogain, 2016

Nicox - Our approach
Partnerships have played an integral role in Nicox’s growth and the Company has demonstrated its expertise in managing successful international alliances with both leading pharmaceutical companies and biotechs. A significant number of the Company’s nitric oxide-donating compounds have been developed through collaborations with leading international pharmaceutical companies including Bausch + Lomb, Astra Zeneca, Merck, Pfizer.

Partnerships accelerate the advancement of Nicox’s research and development activities, allowing us to share and build our expertise and endorse the company’s nitric oxide-donating research platform.

The Company expects partnerships to continue to have a significant place in its future development both through the partnering of assets already advanced by Nicox and through allowing us to access innovative science from external sources.

We are always interested in hearing about potential collaborations and seek partners with complementary strengths who share our values; do not hesitate to contact us if you share our passion for visible science.

Our partners
Leadership team

Nicox is led by a team of experienced professionals whose combined expertise covers research, clinical development, regulatory interactions, finance, business and corporate development, alliance management and communication. This experience was acquired in leading pharmaceutical and biotech companies and the team includes Michele Garufi and Elisabeth Robinson, two of Nicox’s co-founders.

Board of directors

Nicox is proud to present its Board of Directors, whose members are highly experienced in the pharmaceutical and biotech industry.